Giovanna Capaldi Fortunato

Dr. Giovanna Capaldi Fortunato

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
BCBruna Almeida Furquim de Camargo
Bruna Almeida Furquim de Camargo
LSLarissa Spósito
Larissa Spósito
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
GCGabriela Corrêa Carvalho
Gabriela Corrêa Carvalho
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Due to the high adaptability of Helicobacter pylori and the low targeting specificity of the drugs normally used in pharmacological therapy, the strains are becoming increasingly resistant to these drugs, making it difficult to eradicate the infection. Thus, the search for new therapeutic approaches has been considered urgent. The incorporation of drugs in advanced drug delivery systems, such as nano and microparticles, would allow the improvement of the retention time in the stomach and the prolongation of drug release rates at the target site. Because of this, the present review article aims to highlight the use of micro and nanoparticles as important technological tools for the treatment of H. pylori infections, focussing on the main nanotechnological systems, including nanostructured lipid carriers, liposomes, nanoemulsion, metallic nanoparticles, and polymeric nanoparticles, as well as microtechnological systems such as gastroretentive dosage forms, among them mucoadhesive, magnetic and floating systems were highlighted.

1 June 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MRMatheus Aparecidos Dos Santos Ramos
Matheus Aparecidos Dos Santos Ramos
LTLuciani De Toledo
Luciani De Toledo
LSLarissa Spósito
Larissa Spósito
Gabriel Davi MarenaGabriel Davi Marena
Gabriel Davi Marena
LLLaura Caminitti de Lima
Laura Caminitti de Lima
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

10 January 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JDJaqueline Lopes Damasceno
Jaqueline Lopes Damasceno
YAYadira Fernández Arnet
Yadira Fernández Arnet
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
LGLuiza Girotto
Luiza Girotto
Gabriel Davi MarenaGabriel Davi Marena
Gabriel Davi Marena
CMCarlos Henrique Martins
Carlos Henrique Martins
Trees of the Copaifera genus are native to the tropical regions of Latin America and Western Africa. Copaifera sp is widely used as a popular medicine and it has various ethnopharmacological indications, including gonorrhea, bronchitis, asthma, skin ulcers, ulcers, sore throat, uterine infections, general inflammations, cancer, and leishmanioses. Kaurenoic acid is a naturally occurring diterpene found in Copaifera and has been used as an anti-inflammatory, treatment of ulcer, leishmaniasis, and cancer. Bearing in mind the fact that the Ames test is an excellent tool to assess the safety of extracts, oils, and phytochemicals isolated from medicinal plants, from it, we evaluate the mutagenic potential of four species, between oleoresins (C. oblongifolia; C. langsdorffii) and leaves extracts (C. lucens; C. multijuga), of the Copaifera genus and also of kaurenoic acid, which is one of its major compounds. The results showed that the Copaifera spp. and kaurenoic acid did not induce an increase in the number of revertant colonies, without mutagenic effect in experiments, in the all concentrations evaluated by Ames test. The results obtained in our study support the safe use of the Copaifera genus medicinal plants selected and of kaurenoic acid.

7 April 2021 in Journal of Drug Targeting
Verified
Journal Article
Closed access
LSLarissa Spósito
Larissa Spósito
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
BCBruna Almeida Furquim de Camargo
Bruna Almeida Furquim de Camargo
MRMatheus Aparecidos Dos Santos Ramos
Matheus Aparecidos Dos Santos Ramos
MSMaurício Palmeira de Souza
Maurício Palmeira de Souza
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Peptic ulcer disease (PUD) is a common condition that is induced by acid and pepsin causing lesions in the mucosa of the duodenum and stomach. The pathogenesis of PUD is a many-sided scenario, which involves an imbalance between protective factors, such as prostaglandins, blood flow, and cell renewal, and aggressive ones, like alcohol abuse, smoking, Helicobacter pylori colonization, and the use of non-steroidal anti-inflammatory drugs. The standard oral treatment is well established; however, several problems can decrease the success of this therapy, such as drug degradation in the gastric environment, low oral bioavailability, and lack of vectorization to the target site. In this way, the use of strategies to improve the effectiveness of these conventional drugs becomes interesting. Currently, the use of drug delivery systems is being explored as an option to improve the drug therapy limitations, such as antimicrobial resistance, low bioavailability, molecule degradation in an acid environment, and low concentration of the drug at the site of action. This article provides a review of oral drug delivery systems looking for improving the treatment of PUD.

15 November 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
Gabriel Davi MarenaGabriel Davi Marena
Gabriel Davi Marena
DSDébora Eduarda Soares Silva
Débora Eduarda Soares Silva
TRTamara Renata Machado Ribeiro
Tamara Renata Machado Ribeiro
CMCristiano Gallina Moreira
Cristiano Gallina Moreira
TBTaís Maria Bauab
Taís Maria Bauab
Introduction: The increasing prevalence of fungal infections, particularly those caused by Candida albicans, presents a significant clinical challenge due to the emergence of drug-resistant strains. Silver (I) coordination complexes show promise as antifungal agents; however, their poor water solubility limits clinical application. Methods: In this study, we developed and characterized a lipid nanoemulsion (Ag-LN) to enhance the delivery and activity of a silver (I) complex. Results: The formulation exhibited nanoscale size, spherical morphology, and stability for up to 60 days. Ag-LN showed potent antifungal effects, preventing biofilm formation and eradicating mature biofilms. Importantly, nanoencapsulation preserved antifungal activity while reducing mutagenic potential and acute toxicity compared with the free compound. Conclusions: These findings support Ag-LN as a promising antifungal platform for future preclinical studies.

2 September 2026 in Therapeutic Delivery
Verified
Journal Article
Closed access
GFGiovanna Capaldi Fortunato
Giovanna Capaldi Fortunato
Jonatas DuarteJonatas Duarte
Jonatas Duarte
MLMarcela Tavares Luiz
Marcela Tavares Luiz
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
1. Abiraterone acetate (AbA) is a prodrug that is taken orally and is commonly used in the treatment of metastatic castration-resistant prostate cancer (mCRPC), as well as more recently in the trea...